H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza revenue guidance for around 10% year-over-year growth compares to near 15% growth consensus around the midpoint, notes the analyst, who believes the “conservative” Ingrezza guidance can be due to competition pressure and from seasonal payer dynamics. However, Crenessity demonstrates “encouraging growth potential,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $179 from $184 at BofA
- Neurocrine price target lowered to $163 from $172 at Canaccord
- Neurocrine Biosciences Reports Strong Growth in 2024
- Closing Bell Movers: Amazon slips 4% on soft Q1 outlook, capex plans
- Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93